Non-Hodgkin’s lymphoma infiltration refers to the metastasis of non-Hodgkin’s lymphoma from the original site of the disease to other tissues or organs, and the patient will have enlarged lymph nodes, and the adjacent lymph nodes will merge to form a mass and will adhere to the skin. In addition, when non-Hodgkin’s lymphoma invades the lungs, the patient will have cough, dyspnea and chest tightness. If non-Hodgkin’s lymphoma invades the pharyngeal lymphatic ring, it will cause symptoms such as nasal congestion, nosebleed, and difficulty in swallowing. In addition, if non-Hodgkin’s lymphoma invades the digestive tract, patients will manifest abdominal pain, abdominal mass, diarrhea and so on. In addition, patients will also have systemic symptoms, such as fatigue, night sweats (abnormal sweating after going to sleep, and sweating stops after waking up), lethargy, fever, and so on. For patients who develop infiltration of non-Hodgkin’s lymphoma, chemotherapeutic drugs such as doxorubicin and cyclophosphamide, as well as targeted drugs such as rituximab and ibrutinib, need to be used under the guidance of doctors. In addition, patients can also be treated with radiation irradiation therapy, or hematopoietic stem cell transplantation. Generally, non-Hodgkin’s lymphoma has a high degree of malignancy and a poor prognosis. It is suggested that non-Hodgkin’s lymphoma infiltration needs timely medical treatment, and need to follow the doctor’s advice to choose the appropriate measures for treatment.